The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension

Research output: Contribution to journalArticle

2 Citations (Scopus)
95 Downloads (Pure)

Abstract

Obesity-related hypertension is commonly characterized by increased sympathetic nerve activity and is therefore acknowledged as a predominantly neurogenic form of hypertension. The sustained sympatho-excitation not only contributes to the rise in blood pressure but also elicits a vicious cycle which facilitates further weight gain and progression of associated co-morbidities. While weight loss and exercise remain at the forefront of therapy for obesity and obesity-related hypertension, the difficulties in achieving and maintaining long-term weight loss with lifestyle measures and the variable blood pressure response to weight loss often necessitate prescription of antihypertensive drug therapy. Remarkably, there are no specific recommendations for pharmacologic treatment for obese patients with arterial hypertension in any of the current guidelines and general principles of antihypertensive treatment are applied. The use of β-blockers and diuretics is commonly discouraged as first- or second-line therapy due to their unfavorable metabolic effects. This review explores evolving therapeutic strategies which based on their interference with pathophysiologic mechanism relevant in the context of obesity may guide optimized treatment of obesity-related hypertension.

Original languageEnglish
Article number99
JournalCurrent Hypertension Reports
Volume19
Issue number12
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Obesity
Hypertension
Weight Loss
Antihypertensive Agents
Therapeutics
Blood Pressure
Prescription Drugs
Diuretics
Weight Gain
Inhibition (Psychology)
Life Style
Guidelines
Exercise
Morbidity
Drug Therapy

Cite this

@article{dd0bdf50ed9f4cc381c67cd00018e4e8,
title = "The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension",
abstract = "Obesity-related hypertension is commonly characterized by increased sympathetic nerve activity and is therefore acknowledged as a predominantly neurogenic form of hypertension. The sustained sympatho-excitation not only contributes to the rise in blood pressure but also elicits a vicious cycle which facilitates further weight gain and progression of associated co-morbidities. While weight loss and exercise remain at the forefront of therapy for obesity and obesity-related hypertension, the difficulties in achieving and maintaining long-term weight loss with lifestyle measures and the variable blood pressure response to weight loss often necessitate prescription of antihypertensive drug therapy. Remarkably, there are no specific recommendations for pharmacologic treatment for obese patients with arterial hypertension in any of the current guidelines and general principles of antihypertensive treatment are applied. The use of β-blockers and diuretics is commonly discouraged as first- or second-line therapy due to their unfavorable metabolic effects. This review explores evolving therapeutic strategies which based on their interference with pathophysiologic mechanism relevant in the context of obesity may guide optimized treatment of obesity-related hypertension.",
keywords = "Antihypertensive medications, Obesity-related hypertension, Pathophysiology, Pharmacotherapy, Sympathetic activation",
author = "Revathy Carnagarin and Cynthia Gregory and Omar Azzam and Hillis, {Graham S.} and Carl Schultz and Watts, {Gerald F.} and Damon Bell and Vance Matthews and Schlaich, {Markus P.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s11906-017-0795-1",
language = "English",
volume = "19",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "12",

}

TY - JOUR

T1 - The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension

AU - Carnagarin, Revathy

AU - Gregory, Cynthia

AU - Azzam, Omar

AU - Hillis, Graham S.

AU - Schultz, Carl

AU - Watts, Gerald F.

AU - Bell, Damon

AU - Matthews, Vance

AU - Schlaich, Markus P.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Obesity-related hypertension is commonly characterized by increased sympathetic nerve activity and is therefore acknowledged as a predominantly neurogenic form of hypertension. The sustained sympatho-excitation not only contributes to the rise in blood pressure but also elicits a vicious cycle which facilitates further weight gain and progression of associated co-morbidities. While weight loss and exercise remain at the forefront of therapy for obesity and obesity-related hypertension, the difficulties in achieving and maintaining long-term weight loss with lifestyle measures and the variable blood pressure response to weight loss often necessitate prescription of antihypertensive drug therapy. Remarkably, there are no specific recommendations for pharmacologic treatment for obese patients with arterial hypertension in any of the current guidelines and general principles of antihypertensive treatment are applied. The use of β-blockers and diuretics is commonly discouraged as first- or second-line therapy due to their unfavorable metabolic effects. This review explores evolving therapeutic strategies which based on their interference with pathophysiologic mechanism relevant in the context of obesity may guide optimized treatment of obesity-related hypertension.

AB - Obesity-related hypertension is commonly characterized by increased sympathetic nerve activity and is therefore acknowledged as a predominantly neurogenic form of hypertension. The sustained sympatho-excitation not only contributes to the rise in blood pressure but also elicits a vicious cycle which facilitates further weight gain and progression of associated co-morbidities. While weight loss and exercise remain at the forefront of therapy for obesity and obesity-related hypertension, the difficulties in achieving and maintaining long-term weight loss with lifestyle measures and the variable blood pressure response to weight loss often necessitate prescription of antihypertensive drug therapy. Remarkably, there are no specific recommendations for pharmacologic treatment for obese patients with arterial hypertension in any of the current guidelines and general principles of antihypertensive treatment are applied. The use of β-blockers and diuretics is commonly discouraged as first- or second-line therapy due to their unfavorable metabolic effects. This review explores evolving therapeutic strategies which based on their interference with pathophysiologic mechanism relevant in the context of obesity may guide optimized treatment of obesity-related hypertension.

KW - Antihypertensive medications

KW - Obesity-related hypertension

KW - Pathophysiology

KW - Pharmacotherapy

KW - Sympathetic activation

UR - http://www.scopus.com/inward/record.url?scp=85032566397&partnerID=8YFLogxK

U2 - 10.1007/s11906-017-0795-1

DO - 10.1007/s11906-017-0795-1

M3 - Article

VL - 19

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 12

M1 - 99

ER -